Bicara Therapeutics Inc. Common Stock (BCAX) vs Immatics N.V. (IMTX)
A side-by-side comparison of Bicara Therapeutics Inc. Common Stock and Immatics N.V. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BCAX
Bicara Therapeutics Inc. Common Stock
$17.05HealthcareDelayed quote: Oct 6, 2026, 10:05 AM EDT
IMTX
Immatics N.V.
$7.55HealthcareDelayed quote: Oct 6, 2026, 10:05 AM EDT
Total return — BCAX vs IMTX
growth of $100 · dividends reinvested · last 2yBCAX -26.1% (-14.1%/yr)IMTX -38.0% (-21.2%/yr)BCAX compounded faster over this window
BCAX IMTX
BCAX vs IMTX: by the numbers
- •BCAX is the larger company ($1.12B vs $1.01B market cap).
- •Both run net losses; BCAX's is the smaller (0.00% vs -493.26% net margin).
Metrics side by side
Valuation
| Metric | BCAX | IMTX |
|---|---|---|
| P/S ratio | N/A | 20.85 |
| P/B ratio | 2.39 | 2.22 |
Profitability
| Metric | BCAX | IMTX |
|---|---|---|
| Gross margin | 0.00% | 100.00% |
| Operating margin | 0.00% | -377.11% |
| Net margin | 0.00% | -493.26% |
| ROE | -39.54% | -52.47% |
| ROIC | -42.98% | -53.36% |
Growth (annualized)
| Metric | BCAX | IMTX |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 6.40% |
| Total return CAGR (5Y) | N/A | -9.88% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.